Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 19/20 | 0.96 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.77 |
| ▸ | CSF1R | P07333 | 2/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.53 |
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | CIT | O14578 | 1/20 | 0.52 |
| ▸ | MUSK | O15146 | 1/20 | 0.52 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.52 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | STK10 | O94804 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | YES1 | P07947 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488850 | 1.00 | AURKA (0.96) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL3488987 | 0.98 | AURKA (1.00) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL3490173 | 0.98 | AURKA (1.00) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL3489346 | 0.93 | AURKA (0.90) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL6525975 | 0.93 | AURKA (0.90) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL5492704 | 0.92 | AURKA (0.83) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL5492712 | 0.92 | AURKA (0.83) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL5495265 | 0.92 | AURKA (0.83) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL5495253 | 0.92 | AURKA (0.83) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL3489216 | 0.92 | AURKA (0.81) | AURKAAURKBCSF1RPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268841-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | claimed |
| US-20100069412-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | claimed |
| US-9567358-B2 | Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide | ASTRAZENECA AB (SE) | 2017-02-14 | — | — | US | disclosed |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-29 | — | — | US | disclosed |
| US-9018191-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2014-06-12 | — | — | US | disclosed |
| US-8268841-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-20100069412-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| US-7528121-B2 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | ASTRAZENECA AB (SE) | 2009-05-05 | — | — | US | disclosed |
| EP-1847539-A1 | Quinazoline derivatives | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| EP-1578755-B1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | EP | disclosed |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| EP-1578755-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058781-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | AURKA 220/4885AURKB 575/4885CSF1R 1763/4885 |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ABL1, NQO1, NQO2 | AURKA 492/4885AURKB 634/4885CSF1R 1502/4885 |
| US-20100069412-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | AURKA 220/4885AURKB 575/4885CSF1R 1763/4885 |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885CSF1R 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.